Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven R Goldsmith

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Journal of the American College of Cardiology|December 6, 2005
Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trialBradley A Bart, Andrew Boyle, Alan J Bank, et al.
Journal of Cardiac Failure|May 30, 2009
Results of the Prospective Minnesota Study of ECHO/TDI in Cardiac Resynchronization Therapy (PROMISE-CRT) studyAlan J Bank, Christopher L Kaufman, Aaron S Kelly, et al.
European Journal of Heart Failure|August 11, 2025
A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure: The AVANTI trialJames E Udelson, Steven R Goldsmith, Daniel Burkhoff, et al.
Journal of Cardiac Failure|February 27, 2016
Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal DysfunctionYuya Matsue, Makoto Suzuki, Sho Torii, et al.
Journal of Cardiac Failure|August 3, 2016
Corrigendum to "Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction" Journal of Cardiac Failure, Vol. 22, No. 6, June 2016, pp. 423-432Yuya Matsue, Makoto Suzuki, Sho Torii, et al.
International Journal of Cardiology|July 13, 2016
Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunctionYuya Matsue, Makoto Suzuki, Sho Torii, et al.
Heart and Vessels|July 13, 2017
Prognostic importance of sodium level trajectory in acute heart failureYuya Matsue, Kenji Yoshioka, Makoto Suzuki, et al.
Circulation. Heart Failure|December 15, 2012
Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trialDavid E Lanfear, Hani N Sabbah, Steven R Goldsmith, et al.
Journal of Cardiac Failure|November 13, 2012
Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudyAchal Gupta, Eugene Braunwald, Steven McNulty, et al.
European Journal of Heart Failure|March 20, 2026
Pancreatic Involvement During Acute Heart Failure: Insights from the AVANTI trialMarlene A T Vijver, Olivier C Dams, Geert H D Voordes, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Journal of the American College of Cardiology|December 6, 2005
Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trialBradley A Bart, Andrew Boyle, Alan J Bank, et al.
Journal of Cardiac Failure|May 30, 2009
Results of the Prospective Minnesota Study of ECHO/TDI in Cardiac Resynchronization Therapy (PROMISE-CRT) studyAlan J Bank, Christopher L Kaufman, Aaron S Kelly, et al.
European Journal of Heart Failure|August 11, 2025
A multicentre, randomized, double-blind, active and placebo-controlled study of pecavaptan, a dual V1a/V2 vasopressin receptor antagonist, in patients with acute heart failure: The AVANTI trialJames E Udelson, Steven R Goldsmith, Daniel Burkhoff, et al.
Journal of Cardiac Failure|February 27, 2016
Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal DysfunctionYuya Matsue, Makoto Suzuki, Sho Torii, et al.
Journal of Cardiac Failure|August 3, 2016
Corrigendum to "Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction" Journal of Cardiac Failure, Vol. 22, No. 6, June 2016, pp. 423-432Yuya Matsue, Makoto Suzuki, Sho Torii, et al.
International Journal of Cardiology|July 13, 2016
Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunctionYuya Matsue, Makoto Suzuki, Sho Torii, et al.
Heart and Vessels|July 13, 2017
Prognostic importance of sodium level trajectory in acute heart failureYuya Matsue, Kenji Yoshioka, Makoto Suzuki, et al.
Circulation. Heart Failure|December 15, 2012
Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trialDavid E Lanfear, Hani N Sabbah, Steven R Goldsmith, et al.
Journal of Cardiac Failure|November 13, 2012
Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudyAchal Gupta, Eugene Braunwald, Steven McNulty, et al.
European Journal of Heart Failure|March 20, 2026
Pancreatic Involvement During Acute Heart Failure: Insights from the AVANTI trialMarlene A T Vijver, Olivier C Dams, Geert H D Voordes, et al.
Pageof 6